home / stock / huma / huma news

HUMA News and Press, Humacyte Inc. From 03/18/24

Stock Information
Company Name: Humacyte Inc.
Stock Symbol: HUMA
Market: NASDAQ
Website: humacyte.com
Menu
HUMA HUMA Quote HUMA Short HUMA News HUMA Articles HUMA Message Board
Get HUMA Alerts

News, Short Squeeze, Breakout and More Instantly...
HUMA - Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024

DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31,...
HUMA - Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference

DURHAM, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Execu...

HUMA - Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced today announced the pricing of an underwritten public offering of 13,4...

HUMA - Humacyte, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it has commenced an underwritten public offering of its common st...
HUMA - Humacyte gains on FDA priority review for bioengineered blood vessel

2024-02-09 08:47:48 ET More on Humacyte Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity Seeking Alpha’s Quant Rating on Humacyte Historical earnings data for Humacyte Financial information for Humacyte Read the full a...

HUMA - Biotech Stocks in Focus

2024-01-24 09:10:00 ET January 24, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of new stocks to watch in Biotech, Defense, Energy and Homebuilder sectors. Today's stocks have been added to Invest...

HUMA - DBX, CMPS and EWBC are among after hour movers

2024-01-23 17:06:11 ET Gainers: Zoomcar Holdings ( ZCAR ) +8% . Netflix ( NFLX ) +7% . Cricut ( CRCT ) +5% . Tenaya Therapeutics ( TNYA ) +5% . ARS Pharmaceuticals ( SPRY ) +4% . Losers: Humacyte ( HUMA ) -5% . ...
HUMA - EXTR, URBN and APPI are among after hour movers

2024-01-09 16:20:04 ET Gainers: WISeKey International  ( WKEY ) +14% . MaxCyte ( MXCT ) +8% . Humacyte. ( HUMA ) +8% . Agora ( API ) +6% . Urban Outfitters ( URBN ) +6% . Losers: Grifols ( GRFS ) -9% . Ex...

HUMA - Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Execut...

HUMA - Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity

2023-11-20 19:28:16 ET Summary Humacyte is a developer of implantable regenerative human tissue for trauma and other uses. Their core technology, Human Acellular Vessel, has shown higher rates of patency, lower amputation rates, and lower infection rates compared to synthetic graf...
Previous 10 Next 10